Table of Contents
Cannabis use during pregnancy has become an increasingly common and increasingly complicated topic. As legalization expands and cultural attitudes toward cannabis shift, more pregnant individuals are considering or actively using cannabis products — often for the very real symptoms of pregnancy like nausea, anxiety, and insomnia. Survey data suggests that cannabis use among pregnant women in the United States has roughly doubled over the past decade, with rates particularly high during the first trimester when morning sickness is most severe.
Yet every major medical organization in the world — from the American College of Obstetricians and Gynecologists (ACOG) to the World Health Organization (WHO) — recommends against cannabis use during pregnancy and breastfeeding. This article presents the current state of the evidence as objectively as possible, explaining what researchers know, what they do not yet know, and why the medical consensus errs strongly on the side of caution.
Current medical consensus on cannabis and pregnancy
The position of the medical establishment is clear and unified: pregnant and breastfeeding individuals should not use cannabis in any form. This recommendation comes from the American College of Obstetricians and Gynecologists (ACOG), the American Academy of Pediatrics (AAP), the Society of Obstetricians and Gynaecologists of Canada (SOGC), the U.S. Surgeon General, and the FDA. These organizations base their recommendations on the precautionary principle — when the potential risk involves a developing fetus, the bar for safety must be set extremely high.
The Surgeon General issued a specific advisory on cannabis use during pregnancy in 2019, citing concerns about the effects of THC on fetal brain development. The advisory emphasized that no amount of cannabis use during pregnancy or adolescence is known to be safe, and it urged healthcare providers to screen for cannabis use and counsel patients about the potential risks. This advisory was notable because it was issued at a time when cannabis potency was at historic highs — the average THC content of cannabis products had risen from roughly 4% in the 1990s to over 15% by 2019, with many concentrates and edibles containing far higher levels.
It is important to understand why the consensus is so definitive despite the research being somewhat incomplete. Conducting randomized controlled trials of cannabis use in pregnant women is ethically impossible — you cannot intentionally expose fetuses to a potentially harmful substance to measure the effects. This means the evidence base relies primarily on observational studies, animal research, and epidemiological data, all of which have inherent limitations. However, when the available evidence consistently points toward potential harm — particularly to a population that cannot consent (the fetus) — medical ethics demands a conservative approach.
Some advocates argue that the medical establishment is overly cautious and that cannabis is being held to a stricter standard than other substances. While it is true that research limitations make definitive conclusions difficult, the biological plausibility of harm is well established. THC crosses the placental barrier, the fetal endocannabinoid system is active from early in development, and animal studies have demonstrated clear neurodevelopmental effects. Given these facts, the medical consensus is not merely political or cultural — it is rooted in biology.
How THC crosses the placental barrier
The placenta serves as the interface between mother and fetus, filtering nutrients and oxygen while ideally blocking harmful substances. However, the placenta is not an impenetrable shield, and THC passes through it with relative ease. As a lipophilic (fat-soluble) molecule, THC readily crosses cell membranes, including the multiple cell layers that constitute the placental barrier. Studies have shown that approximately 10% to 30% of the THC in maternal blood reaches the fetal circulation, with higher transfer rates occurring during the later stages of pregnancy as the placenta thins.
What makes this particularly concerning is the timing of fetal brain development. The endocannabinoid system begins functioning very early in pregnancy — CB1 receptors appear in the fetal brain by the 14th week of gestation. This system plays a crucial role in neural development, guiding the proliferation, migration, and differentiation of neurons. Endocannabinoids like anandamide act as signaling molecules that help determine where neurons go and how they connect. When exogenous THC enters this system, it has the potential to disrupt these precisely orchestrated developmental processes.
Animal studies have provided compelling evidence for this concern. Research in rodents has shown that prenatal THC exposure alters the expression of genes involved in neuronal development, disrupts the formation of dopaminergic and glutamatergic circuits, and produces lasting changes in the structure and function of the prefrontal cortex and hippocampus — brain regions critical for decision-making, attention, and memory. While animal models do not perfectly predict human outcomes, the consistency of these findings across multiple species and research groups is difficult to dismiss.
CBD also crosses the placental barrier, though its effects on fetal development are even less well understood than those of THC. Because CBD modulates endocannabinoid signaling through indirect mechanisms — including inhibition of the FAAH enzyme that breaks down anandamide — it has the potential to alter endocannabinoid tone in the developing fetus even without directly activating cannabinoid receptors. The FDA has explicitly stated that it advises against the use of CBD during pregnancy, noting that the available evidence is insufficient to establish safety.
Research on fetal development and cannabis
The research on prenatal cannabis exposure and birth outcomes has grown considerably, with several large-scale studies providing useful data despite the methodological challenges inherent in observational research. The most consistently reported finding is an association between cannabis use during pregnancy and reduced birth weight. A 2016 meta-analysis published in BMJ Open that pooled data from 24 studies found that women who used cannabis during pregnancy were significantly more likely to have babies with low birth weight (below 2,500 grams) and to deliver preterm (before 37 weeks of gestation).
However, the relationship between cannabis and birth outcomes is complicated by confounding factors. Women who use cannabis during pregnancy are more likely to also use tobacco, alcohol, or other substances, and they may differ from non-users in terms of socioeconomic status, nutrition, prenatal care access, and other variables that independently affect birth outcomes. Studies that carefully control for tobacco use — the most significant confounder — have found smaller but still statistically significant associations between cannabis use and reduced birth weight. A 2020 study using data from the Ontario Birth Registry analyzed over 660,000 births and found that cannabis use was associated with a modest but significant increase in preterm birth and small-for-gestational-age infants, even after adjusting for tobacco and other confounders.
The long-term neurodevelopmental effects of prenatal cannabis exposure have been examined in several prospective cohort studies, the most notable being the Ottawa Prenatal Prospective Study (OPPS) and the Maternal Health Practices and Child Development (MHPCD) study. These studies have followed children from birth into adolescence and adulthood, providing some of the best available longitudinal data. Both studies found subtle but measurable differences in executive function, attention, and impulse control among children with prenatal cannabis exposure, particularly those whose mothers used heavily during the first trimester. The MHPCD study also found associations with increased depressive symptoms and delinquent behavior in adolescence.
More recently, the Adolescent Brain Cognitive Development (ABCD) study — the largest long-term study of brain development in the United States — has begun to report findings on prenatal substance exposure. Preliminary analyses have shown that children with prenatal cannabis exposure exhibit differences in brain structure, including alterations in cortical thickness and white matter integrity. These differences were associated with increased psychopathology symptoms and lower cognitive test scores, though the effect sizes were generally small and the clinical significance remains debated.
It is essential to note what the research does not show: there is no evidence that prenatal cannabis exposure causes severe birth defects, intellectual disability, or major structural brain abnormalities. The effects observed in research are subtle — they are statistical differences that emerge at the population level and may not be noticeable in any individual child. However, subtle does not mean insignificant. Small shifts in attention, impulse control, and executive function can have meaningful impacts on academic performance and social development over the course of a child's life.
Cannabis and breastfeeding
The transfer of cannabinoids into breast milk is well documented and presents a clear concern for nursing mothers. THC is highly lipophilic, and breast milk is one of the fattiest fluids the body produces, creating an efficient vehicle for cannabinoid delivery to the infant. A 2018 study published in Pediatrics found that THC was detectable in 63% of breast milk samples from women who reported using cannabis, with THC concentrations persisting for up to six days after a single use. This extended detection window reflects THC's accumulation in body fat and its slow release into breast milk over time.
The infant's exposure through breast milk is particularly concerning because of the immaturity of the newborn's metabolic systems. Adults process THC through a well-developed cytochrome P450 enzyme system in the liver, but this system is not fully functional in infants. This means that cannabinoids may accumulate to higher effective concentrations in the infant's body than they would in an adult's, and they may take longer to clear. The infant's blood-brain barrier is also more permeable than an adult's, potentially allowing greater cannabinoid access to the developing brain.
Despite these pharmacological concerns, the direct evidence of harm from cannabis exposure through breast milk is limited. No studies have definitively shown that the levels of THC typically found in breast milk cause measurable harm to infants. A small 1990 study found an association between maternal cannabis use during breastfeeding and slightly reduced motor development at one year of age, but the study was too small and too confounded to draw firm conclusions. More recent research has not yet filled this gap.
Both the American Academy of Pediatrics (AAP) and ACOG recommend that breastfeeding mothers abstain from cannabis use entirely. However, they also emphasize that the benefits of breastfeeding are substantial and well-documented, and that cannabis use alone is not sufficient reason to advise against breastfeeding. In other words, if a mother is using cannabis and cannot stop, breastfeeding is still generally preferable to formula feeding — but cessation of cannabis use is the ideal goal. The AAP advises healthcare providers to have non-judgmental conversations with nursing mothers about cannabis use and to help them weigh the risks and benefits in their specific circumstances.
Safer alternatives for pregnancy symptoms
Understanding why pregnant individuals turn to cannabis is essential for offering meaningful alternatives. The most commonly cited reason is nausea and vomiting — morning sickness affects up to 80% of pregnant women, and in its severe form (hyperemesis gravidarum), it can be debilitating and even life-threatening. Other symptoms that drive cannabis use include anxiety, insomnia, chronic pain, and appetite loss. Dismissing these symptoms or simply telling patients to "tough it out" is unlikely to change behavior; offering effective alternatives is far more productive.
For nausea and vomiting: Several evidence-based treatments are available. Ginger — in the form of ginger tea, ginger candies, or ginger capsules — has been shown in multiple clinical trials to significantly reduce pregnancy-related nausea and is considered safe by ACOG. Vitamin B6 (pyridoxine), taken at 10 to 25 mg three times daily, is another first-line recommendation. For more severe nausea, the prescription medication doxylamine-pyridoxine (Diclegis/Diclectin) has an extensive safety record in pregnancy. Acupressure wristbands targeting the P6 (Neiguan) point have also shown benefit in some studies. For hyperemesis gravidarum that does not respond to these measures, ondansetron (Zofran) may be prescribed under medical supervision.
For anxiety: Cognitive behavioral therapy (CBT) is the gold-standard non-pharmacological treatment for anxiety during pregnancy and has no known risks to the fetus. Mindfulness-based stress reduction (MBSR) programs designed for pregnant women have also shown significant benefit. Regular moderate exercise — such as walking, swimming, or prenatal yoga — has demonstrated anxiolytic effects comparable to some medications. For severe anxiety that requires pharmacological treatment, certain SSRIs (such as sertraline) have been used during pregnancy with a generally favorable risk-benefit profile, though this decision should be made in close consultation with an obstetrician and psychiatrist.
For insomnia: Sleep hygiene practices — including consistent sleep and wake times, limiting screen exposure before bed, maintaining a cool and dark sleeping environment, and avoiding caffeine after noon — form the foundation of insomnia management during pregnancy. A warm bath before bed, relaxation techniques, and progressive muscle relaxation can also help. Melatonin, while commonly used for sleep, has not been adequately studied in pregnancy and is not recommended by most obstetricians. Doxylamine, an antihistamine with sedating properties and a long safety record in pregnancy (it is one component of Diclegis), may be used for short-term insomnia relief under medical guidance.
For chronic pain: Acetaminophen (Tylenol) remains the safest over-the-counter pain reliever during pregnancy, though it should be used at the lowest effective dose for the shortest possible duration. Physical therapy, prenatal massage, warm compresses, and gentle stretching can help manage musculoskeletal pain. For severe or chronic pain conditions, your healthcare provider may recommend other approaches tailored to your specific situation. NSAIDs (ibuprofen, naproxen) should be avoided during pregnancy, especially in the third trimester, due to risks of premature closure of the fetal ductus arteriosus.
What to tell your healthcare provider
One of the most significant barriers to reducing cannabis use during pregnancy is the fear of judgment — or worse, legal consequences — that prevents many pregnant individuals from being honest with their healthcare providers. This fear is not unfounded: in some states, prenatal substance use can trigger involvement from child protective services, and urine drug testing during pregnancy is common, particularly in hospitals that serve lower-income populations. These policies, while intended to protect children, often have the unintended effect of driving cannabis use underground rather than eliminating it.
Despite these concerns, honesty with your healthcare provider is critically important. Your doctor or midwife needs to know what substances you are using in order to provide the safest possible prenatal care. Cannabis use can affect decisions about monitoring, testing, and treatment throughout pregnancy. Providers who are aware of cannabis use can offer appropriate support, discuss harm reduction strategies, and connect patients with resources to help them reduce or stop use. Most healthcare providers today are trained to approach substance use during pregnancy with empathy rather than judgment, and many are genuinely eager to help.
If you have been using cannabis during pregnancy, the most important thing to know is that stopping at any point is beneficial. The fetal brain continues developing throughout all three trimesters and into the postnatal period, so reducing exposure at any stage can reduce potential risk. Do not let guilt about past use prevent you from being honest going forward — your healthcare provider's goal is to support the healthiest possible outcome for you and your baby, not to punish you for past decisions.
If you are finding it difficult to stop using cannabis on your own, ask your provider about support resources. Many communities offer substance use counseling specifically designed for pregnant women, and these programs typically address cannabis alongside other substances in a non-judgmental environment. Some patients find that gradually reducing their dose — rather than stopping abruptly — is more sustainable and avoids the rebound anxiety and insomnia that can accompany sudden cessation. Your provider can help you develop a tapering plan if needed.
Finally, if you used cannabis before knowing you were pregnant — which is extremely common, as many pregnancies are unplanned and cannabis use in early pregnancy often predates pregnancy awareness — try not to catastrophize. The research on prenatal cannabis exposure describes statistical associations and subtle effects, not guaranteed outcomes. Many children with prenatal cannabis exposure develop normally and show no measurable differences from their peers. The best course of action is always to stop use as soon as pregnancy is confirmed and to work with your healthcare team to address the symptoms that were driving your cannabis use through safer alternatives.